EUVIMEDEUVIMED entdecken
Korrektur

Erratum

International Archives of Allergy and Immunology · 21.08.2026 · 1-11

DOI: 10.1159/000553551 ↗

Kurz gefasst

Korrektur in der Zeitschrift International Archives of Allergy and Immunology, online erschienen am 21.08.2026.

AbstractBibliografische AngabenZitieren

Abstract (Originalsprache)

In the article "House Dust Mite Sublingual Immunotherapy for Allergic Rhinoconjunctivitis: Comprehensive Review and Meta-Analytical Evidence" [Int Arch Allergy Immunol. 2026; https://doi.org/10.1159/000551015] by Alqutub et al., Table 1 was published with an error.Table 1.Summary of included studiesStudy IDStudy designCountryTotal participantsIntervention/comparatorsFollow-up, monthsInclusion criteriaConclusionBergmann 2014 [26]RCT7 European countries466HDM SLIT tablets (Stallergenes) 300IR, 500IR, or placebo12Patients (18-50 y) with HDM AR (≥1 y); controlled asthma allowed. The patient must have a positive HDM SPT and sIgE test results. The patient must have baseline symptoms12 months of 300 IR and 500 IR HDM SLIT tablets were efficacious and well tolerated. Efficacy was maintained during the treatment-free follow-up yearGuo 2017 [43]RCTChina96SLIT with a mixture of Der p and Der f extract (Pangramin SLIT; ALK-Abello) or placebo12Patients (5-55 y) with HDM AR (≥1 y) and +/-mild intermittent asthma had positive SPT and/or sIgE responses to HDMSLIT with mixed HDM extract significantly relieved AR symptoms reduced the need for antiallergic drugs compared to placebo, and was well toleratedRoux 2016 [59]RCTCanada266Sublingual tablets of HDM allergen extracts (STG320, Stallergenes) 500IR, 300IR, 100IR, or placebo6Patients (18-55 y) with uncontrolled HDM AR (≥1 y). The patients tested positive for HDM SPT and sIgE. Required baseline allergen challenge symptomsDose-dependent effect of sublingual HDM immunotherapy demonstrated in EEC. 300IR and 500IR doses are to be further evaluated. Well tolerated, AEs were mostly local and mildHoshino 2020 [44]RCTJapan111SQ-HDM SLIT tablet (Torii/ALK-Abello) plus pharmacotherapy or pharmacotherapy alone11Patients (20-65 y) with HDM AR. Positive NPT & sIgE to HDMHigh serum periostin levels at enrollment predict the clinical response (RQLQ improvement) to SQ-HDM SLIT. Serum periostin appears to be a useful biomarkerBozek 2013 [29]RCTPoland32Sublingual allergen-specific immunotherapy (SLIT) with HDM allergens (Staloral 300R, Stallergenes) or placebo36Patients (60-75 y) with HDM AR. Positive SPT, sIgE, and NPT to HDMSLIT for HDM generated significant clinical improvement (nasal symptoms, medication use) in elderly patients compared to placebo, particularly during the heating season. Well toleratedBush 2011 [32]RCTUSA (Madison, WI)21High-dose (4200 AU/d; ∼70 µg Der f 1/d) or low-dose (60 AU/d; ∼1 µg Der f 1/d) Der f SLIT vaccine (Greer Laboratories), or placebo12-18Patients (18-50 y) with Der f AR, +/- mild intermittent asthma. Positive sIgE to Der fHigh-dose Der f SLIT was generally tolerable, increased serum Der f-specific IgG4, and improved bronchial threshold to allergen. Larger US trials are warrantedLin 2015 [47]RCTChina121SLIT with Der.f drops or pharmacotherapy (oral antihistamines)48Patients (4-69 y) with moderate-to-severe Der f AR (≥1.5 y). Positive SPT & sIgEThe 3-year SLIT course was more efficacious than 1-year or 2-year courses. Patients achieved 1-year long-term clinical benefits from HDM SLITTonnel 2004 [62]RCTFrance32SLIT with Der p and Der f 50/50 allergen extract (Stallergenes) tablets (100 IR) or placebo24Patients (7-45 y) with chronic rhinitis +/- moderate asthma. HDM sensitized (SPT & RAST). Required baseline symptomsSLIT tablets showed superiority over placebo for rhinitis scores (total, blocked nose, itching) after 1 and 2 years. Low medication use in all. No serious AEsWang 2013 [63]RCTChina120SLIT with Der p and Der f extract (Zhejiang Wolwo Bio-Pharmaceutical)6Patients (4-60 y) with moderate-to-severe persistent AR +/- asthma. Positive HDM SPT & sIgESLIT with mixed HDM extract is effective and safe for HDM-induced AR. Onset of action as early as 14 weeksNolte 2016 [14]RCTUSA, Canada1,482Daily SQ HDM SLIT-tablet (12 SQ-HDM; Merck/ALK) or placebo for approx. 52 weeks12Patients (≥12 y) with HDM AR/C +/- controlled asthma. Positive HDM SPT & sIgE. Required baseline symptoms12 SQ-HDM SLIT-tablet was well tolerated and improved HDM rhinitis symptoms in North American adolescents and adults. TCRS improved 17% vs. placeboOkamoto 2016 [52]RCTJapan927HDM SLIT tablets (Shionogi/Stallergenes) 300 IR, 500 IR, or placebo12Patients (12-64 y) with HDM AR +/- intermittent asthma. Positive sIgE & NPT. Required baseline symptomsOne-year treatment with 300 IR and 500 IR HDM tablets was effective and safe for AR. The recommended therapeutic dose is 300 IROkubo 2016 [53]RCTJapan946SQ HDM SLIT-tablet (TO-203, Torii/ALK/Merck) 10,000 JAU or 20,000 JAU, or placebo12Patients (12-64 y) with moderate-to-severe HDM AR. Positive sIgE & NPTSQ HDM SLIT-tablet (both doses) confirmed efficacy and a favorable safety profile in Japanese patients with moderate to severe HDM AR. TCRS reduced from week 12Passalacqua 2006 [54]RCTItaly (multicenter)56SLIT with monomeric carbamylated allergoid of HDM (Lais; Lofarma S.p.A.) tablets (1000 AU biweekly) or placebo24Patients (18-50 y) with mild persistent AR +/- mild intermittent asthma. Positive HDM SPT & RASTSLIT with carbamylated allergoid was clinically effective (symptoms, nasal obstruction, drug intake in year 1; QoL item "change in health status") and safe in mite-induced mild diseaseMosbech 2015 [50]RCTEurope (multinational)241SQ HDM SLIT-tablet (1, 3, or 6 SQ-HDM; ALK) or placebo12Patients (≥14 y) with HDM AR & mild-to-moderate HDM asthma. Positive HDM SPT & sIgEEfficacy in mild to severe AR of 6 SQ-HDM vs. placebo was demonstrated by statistically significant improvements in TCRS and RQLQ scores in subjects with AR present at baseline. Well toleratedDidier 2016 [37]RCTFrance, Spain219SLITone ULTRA® HDM mix (50% DP/50% DF) at 50, 150, or 300 SRU.6Patients (≥18 y) with moderate-to-severe persistent HDM AR +/- asthma. Positive SPT & sIgE. Required baseline symptomsDose-response for immunological markers (IgE-blocking factor, IgG4) and safety. 300 SRU showed a better immunological response and was considered the optimal maintenance dose. AEs increased with dose, mostly mild to moderateMacedo 2025 [48]RCTBrazil65SLIT with liquid drops combining extracts of Der p (1 μg Der p 1/day) and Blo t (753 UBE Blo t/day) or placebo12Patients (12-60 y) with moderate/severe persistent AR (≥ 2 y). Sensitized to Der p & B. tropicalis (SPT or sIgE)After 1 year, SLIT drops significantly reduced antihistamine use vs. placebo with a good safety profile. No significant changes in serum total IgE, sIgE, or IgG4 for either allergen vs. placeboHüser 2016 [67]RCTGermany12712-week treatment with sublingual monomeric allergoid tablets (carbamylated, Der p and f; Lofarma S.p.A.) at 300, 1,000, 2000, or 3000 UA/day, or placebo3Patients (18-75 y) with HDM allergic rhinoconjunctivitis (≥2 y). Positive sIgE, SPT, & CPT12-week daily treatment with 2000 UA/day monomeric allergoid SLIT tablets is well tolerated and reduces CPT reaction in HDM-allergic patients. (The primary endpoint of mean allergic severity decrease was not statistically significant)Demoly 2016 [35]RCT12 European countries992SQ HDM SLIT-tablet (ALK) at 6 SQ-HDM or 12 SQ-HDM, or placebo12Patients (18-65y) with moderate-to-severe HDM AR despite pharmacotherapyBoth 6 SQ-HDM and 12 SQ-HDM SLIT tablets confirmed efficacy (reduced TCRS, symptoms, improved QoL) and favorable safety profile in adults with HDM-induced AR. The treatment effect was observed starting from 14 weeks onwardDemoly 2020 [36]RCTEurope, USA, Canada, Israel, Russia1,476300 IR HDM SLIT tablet (Der p: Der f 1:1 extract; Stallergenes Greer) or placebo12Patients (≥12y) with moderate-to-severe HDM ARThe 300 IR sublingual HDM tablet is an effective, safe treatment for HDM-induced allergic rhinitis in adults and adolescents, with clinically meaningful benefits and good tolerabilityPotter 2015 [57]RCTSouth Africa60HDM SLIT (Staloral 300 IR/mL, Der p; Stallergenes) or placebo24Patients (18-60 y) with persistent Der p rhinitis. Positive SPTA good clinical response (≥60% improvement in symptoms and QoL) to 2 years of HDM SLIT is associated with significant decreases in IL-5, IL-13, and IL-4 relative to IFN-γ. Both SLIT and placebo groups showed clinical improvementNolte 2015 [51]RCTAustria (Vienna Challenge Chamber)124HDM SLIT tablet (MK-8237; Merck/ALK-Abello) at 12 DU, 6 DU, or placebo6Patients with HDM AR/C +/- asthma (for EEC study)MK-8237 (12 DU) HDM SLIT-tablet reduced nasal and ocular symptoms in an EEC, exceeding WAO clinical efficacy criteria. The onset of action for 12 DU was week 8. Dose- and time-dependent improvements were observed. Well toleratedGunawardana 2017 [42]RCTUK2312 SQ-HDM SLIT-tablet (MK-8237; Merck & Co/ALK) or placebo3Patients (18-55 y) with HDM AR. Positive SPT & sIgE. Required NAC symptom scores12 SQ-HDM SLIT-tablet significantly increased serum HDM-specific IgG4 and IgE blocking factor and significantly decreased early-phase nasal symptoms after NAC. No significant effects on mucosal cytokinesGuez 2000 [41]RCTFrance72SLIT with Der p f 50/50 allergen extract (Staloral 300 IR/mL; Stallergenes) or placebo24Patients (6-51 y) with chronic rhinitis +/- moderate asthma. HDM sensitized (SPT & RAST). Required baseline symptomsActive SLIT treatment was superior to placebo for rhinitis scores (total, blocked nose, itching) after 1 and 2 years. Low medication use. No serious AEs. Availability of a solid form (tablet) would be progressChen 2020 [34]RCTChina86Treatment group: SLIT with Der f drops (CHANLLERGEN®, WolwoBiotech) + pharmacotherapy on demand. Control group: Standard pharmacotherapy only24Patients (60-75 y) with moderate/severe persistent AR (≥2 y). Positive sIgE to HDMSLIT plus pharmacotherapy provided a greater clinical benefit (CSMS, VAS) than pharmacotherapy alone at 2 years in elderly patients (60-75 years) with HDM-induced AR. 41.9% of patients dropped out within 2 years of SLITJordakieva 2017 [45]RCTAustria77Intervention: HDM allergen challenge in a chamber. Groups: Placebo SLIT, Low-dose HDM SLIT, High-dose HDM SLIT.3-16Pa

Zitieren

APA

(2026). Erratum. International Archives of Allergy and Immunology, 1-11. https://doi.org/10.1159/000553551

Vancouver

Erratum. International Archives of Allergy and Immunology. 2026:1-11. doi:10.1159/000553551

BibTeX
@article{euvimed2026,
  title = {Erratum},
  journal = {International Archives of Allergy and Immunology},
  year = {2026},
  pages = {1--11},
  doi = {10.1159/000553551}
}
Kostenlos starten →